Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).
Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).
复制标题
肝细胞癌（HCC）全身治疗的最新进展
DOI：
10.1007/s11938-021-00346-x
复制
发表时间：
2021-06
期刊：
影响因子：
--
通讯作者：
Dhanasekaran, Renumathy
中科院分区：
文献类型：
--
作者：
Ghaziani, T Tara;Dhanasekaran, Renumathy
在过去的几年里，随着几种一线和二线系统疗法的批准，晚期肝细胞癌(HCC)的管理发生了巨大的变化。在这篇综述中，我们概述了晚期肝癌治疗的最新进展，并讨论了未来的前景。3期临床试验IMBRAVE150最近显示，免疫检查点抑制剂阿特唑珠单抗与抗血管生成剂贝伐单抗联合使用，在治疗初治晚期肝癌方面优于索拉非尼单一疗法。此外，患者现在二线治疗中有多种选择，包括靶向治疗，如索拉非尼、lenvatinib、regorafenib、Cabozantinib、ramucirumab，以及免疫治疗，如atezolizumab和nivolumab，单独或与ipilimumab联合使用。最近在晚期肝细胞癌的治疗方面有了巨大的进步。阿替唑单抗-贝伐单抗联合治疗最近已成为晚期肝癌患者的标准一线治疗方案。此外，免疫治疗药物无论是单独还是与分子靶向治疗相结合，都将在肝细胞癌的治疗中发挥重要作用。
The management of advanced hepatocellular (HCC) has drastically changed in the past few years with approval of several first line and second line systemic therapies. In this review we present an overview of the recent progress in the treatment of advanced HCC and discuss future perspectives. The phase 3 clinical trial IMBRAVE150 has recently shown the combination of an immune checkpoint inhibitor, atezolizumab, with an anti-angiogenic agent, bevacizumab, to be superior to sorafenib monotherapy for treatment-naive advanced HCC. Moreover, patients now have multiple options available in second-line therapy including targeted therapies like sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab and immunotherapies like atezolizumab, and nivolumab either alone or combined with ipilimumab. There has been tremendous recent progress in the management of advanced HCC. Combination therapy with atezolizumab-bevacizumab has recently become the standard first line of therapy for patients with advanced HCC. Additionally, immunotherapy agents are poised to play a significant role in the management of HCC either alone or in combination with molecular targeted therapies.